SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 85 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $901,000 | +11.1% | 102,631 | -5.5% | 0.02% | +25.0% |
| Q3 2019 | $811,000 | +49.1% | 108,576 | +86.0% | 0.02% | +66.7% |
| Q2 2019 | $544,000 | -24.0% | 58,385 | -57.2% | 0.01% | -25.0% |
| Q1 2019 | $716,000 | +76.4% | 136,423 | +49.4% | 0.02% | +45.5% |
| Q4 2018 | $406,000 | +16.3% | 91,339 | +81.5% | 0.01% | +57.1% |
| Q2 2018 | $349,000 | -80.0% | 50,332 | -58.9% | 0.01% | -81.1% |
| Q1 2018 | $1,744,000 | +48.8% | 122,567 | -9.3% | 0.04% | +48.0% |
| Q4 2017 | $1,172,000 | +104.2% | 135,133 | +179.0% | 0.02% | +127.3% |
| Q3 2017 | $574,000 | +48.3% | 48,442 | +75.0% | 0.01% | +37.5% |
| Q2 2017 | $387,000 | – | 27,689 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |